<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019574</url>
  </required_header>
  <id_info>
    <org_study_id>CR845-100201</org_study_id>
    <nct_id>NCT04019574</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Positive-Controlled, Four-way Crossover Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cara Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cara Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, randomized, double-blind (except for moxifloxacin), placebo- and
      positive-controlled, single-site, 4-way crossover study to investigate the effects of single
      therapeutic and supratherapeutic IV doses of difelikefalin (CR845) on the QTc interval in
      healthy adult subjects. Subjects will be randomized to a treatment sequence consisting of 4
      treatment periods with a minimum 5-day washout between treatments. Subjects will receive each
      of the study treatments over the course of the study. Randomized subjects will receive the
      assigned study treatment as a single dose in the fasted state in the morning on Day 1 of each
      treatment period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Actual">October 29, 2019</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QTc change from baseline following CR845 treatment.</measure>
    <time_frame>Baseline, Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in QTc with Bazett correction (QTcB).</measure>
    <time_frame>Baseline, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Heart Rate.</measure>
    <time_frame>Baseline, Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CR845 0.5 mcg/kg IV (Therapeutic Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CR845 3 mcg/kg IV (Supratherapeutic Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CR845 0.5 mcg/kg IV</intervention_name>
    <description>0.5 mcg/kg IV CR845</description>
    <arm_group_label>CR845 0.5 mcg/kg IV (Therapeutic Dose)</arm_group_label>
    <other_name>Difelikefalin 0.5 mcg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CR845 3 mcg/kg IV</intervention_name>
    <description>3 mcg/kg IV CR845</description>
    <arm_group_label>CR845 3 mcg/kg IV (Supratherapeutic Dose)</arm_group_label>
    <other_name>Difelikefalin 3 mcg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg Oral Tablet</intervention_name>
    <description>400 mg Oral Moxifloxacin</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV Placebo as a bolus injection</description>
    <arm_group_label>Placebo IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Body weight between 50 to 120 kg and body mass index within 18 to 29 kg/m2 at
             Screening;

          -  Current nonsmokers who have not used any tobacco- or nicotine-containing products
             (chewed or smoked) or replacement products, including, but not limited to, electronic
             cigarettes, in the 45 days prior to Screening.

        Key Exclusion Criteria:

          -  Past or present diseases, which as judged by the Investigator, may affect the outcome
             of this study;

          -  Any condition or situation that, in the opinion of the Investigator, would prevent
             proper evaluation of the safety or efficacy of the study treatment according to the
             study protocol;

          -  History of hypersensitivity or allergy to moxifloxacin or any other study treatment or
             history of tendonitis or tendon rupture with moxifloxacin or any other quinolone type
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédérique Menzaghi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cara Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cara Therapeutics Study Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Difelikefalin</keyword>
  <keyword>CR845</keyword>
  <keyword>QTc</keyword>
  <keyword>TQT</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

